

AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

LISTING OF CLAIMS:

1. (currently amended) A composition to be buccally administered as a tablet or lozenge, comprising a low dosage lipophilic non-steroidal anti-inflammatory (NSAID) or anti-mycotic drug under an amino acid salt form, wherein the composition ~~can~~ is formulated to be passively diffused into buccal and throat mucous membranes when the composition is totally released, dissolved, coated to the mucous membrane, and then absorbed through mucous.

2. (previously presented) The composition according to claim 1, comprising a substrate that makes possible a slow permucosal diffusion that is uniform and localized to the buccopharyngeal cavity.

3. (previously presented) The composition according to claim 1, wherein at least one anti-inflammatory lipophilic non-steroidal anti-inflammatory drug (NSAID) and/or at least one lipophilic anti-mycotic drug is combined with at least one amino acid.

4. (previously presented) The composition according to claim 3, wherein the amino acid is lysine, arginine, or histidine.

5. (previously presented) The composition according to claim 1, comprising a polymer agent that is a cellulose derivative.

6. (previously presented) The composition according to claim 1, comprising a polymer agent that is a gum.

7. (previously presented) The composition according to claim 1, comprising a polymer agent that is selected from alginic acid and derivatives, carboxy-vinyl polymer, carbomer, macrogols, polyethylene glycols, gelatin, povidone, and pectins.

8. (previously presented) The composition according to claim 1, comprising a carbohydrate substrate.

9. (previously presented) A low dosage tablet comprising the composition according to claim 1, having the following formulation:

- ibuprofen lysinate:	25 mg
- magnesium stearate:	10 mg

- talc: 50 mg
- aspartame: 15 mg
- hydroxy-propyl-methyl  
cellulose: 70 mg
- Arome: 20 mg
- sorbitol: 810 mg

10. (previously presented) A low dosage tablet comprising the composition according to claim 1, having the following formulation:

- ketoprofen lysinate: 5 mg
- magnesium stearate: 10 mg
- talc: 50 mg
- aspartame: 15 mg
- hydroxy-propyl-methyl  
cellulose: 70 mg
- Arome: 20 mg
- sorbitol: 830 mg

11-12. (cancelled)

13. (previously presented) The composition according to claim 2, wherein at least one lipophilic non-steroidal anti-inflammatory drug and/or at least one lipophilic anti-mycotic drug is combined with at least one amino acid.

14. (previously presented) The composition according to claim 2, comprising a polymer agent that is a cellulose derivative.

15. (previously presented) The composition according to claim 3, comprising a polymer agent that is a cellulose derivative.

16. (previously presented) The composition according to claim 4, comprising a polymer agent that is a cellulose derivative se.

17. (previously presented) The composition according to claim 2, comprising a polymer agent that is a gum.

18. (previously presented) The composition according to claim 3, comprising a polymer agent that is a gum.

19. (previously presented) The composition according to claim 4, comprising a polymer agent that is a gum.

20. (previously presented) The composition according to claim 5, comprising a polymer agent that is a gum.

21. (previously presented) A method for producing a medication for treating buccopharyngeal ailments by local permucosal diffusion, comprising providing the composition according to claim 2, and including the composition in the medication.

22. (previously presented) A method for treating buccopharyngeal ailments by local permucosal diffusion comprising administering the tablet according to claim 9 to a subject in need thereof.

23. (previously presented) The composition according to claim 5, wherein the cellulose derivative is carboxy-methyl cellulose that contains soda, hydroxy-ethyl cellulose, hydroxy-propyl cellulose, hydroxy-propyl methyl cellulose or promellose, or carboxy-methyl cellulose.

24. (previously presented) The composition according to claim 6, wherein the gum is guar gum, gum Arabic, or xanthane gum.